Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer
The purpose of this study is to determine the response rate of gemcitabine, cisplatin and erlotinib in metastatic pancreatic cancer.
Metastatic Pancreatic Cancer
DRUG: Gemcitabine, Cisplatin, Erlotinib (Tarceva)
To assess the response rate associated with gemcitabine, erlotinib and cisplatin in patients with advanced pancreatic cancer, Clinically assessed every cycle (month) and radiologically assessed every 2 cycles (6 weeks) with CT scan
The purpose of this study is to determine the response rate of gemcitabine, cisplatin and erlotinib in metastatic pancreatic cancer.